Measures of viral load using Abbott RealTime HIV-1 Assay on venous and fingerstick dried blood spots from provider-collected specimens in Malawian District Hospitals

Journal of Clinical Virology

Volumn 60, Issue 4, 2014, Pages 392-398

  Rutstein, Sarah E ^a,b   Kamwendo, Deborah ^c   Lugali, Lebah ^d   Thengolose, Isaac ^c   Tegha, Gerald ^c   Fiscus, Susan A ^b   Nelson, Julie A E ^b   Hosseinipour, Mina C ^b,c   Sarr, Abdoulaye ^e   Gupta, Sundeep ^e   Chimbwandira, Frank ^f   Mwenda, Reuben ^f   Mataya, Ronald ^g  

^a IL   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA PROJECT   (Malawi)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^f MINISTRY OF HEALTH   (Malawi)

^g LOMA LINDA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; DRIED BLOOD SPOT TESTING; FEMALE; FINGERSTICK DRIED BLOOD SPOT TESTING; HEALTH CARE PERSONNEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; LIMIT OF DETECTION; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALAWI; MALE; NONHUMAN; PLASMA; PRIORITY JOURNAL; PUBLIC HOSPITAL; SENSITIVITY AND SPECIFICITY; TURNAROUND TIME; VEIN PUNCTURE; VENOUS DRIED BLOOD SPOT TESTING; VIREMIA; VIRUS LOAD; BLOOD; BLOOD SAMPLING; COMPARATIVE STUDY; GENETICS; HIV INFECTIONS; HOSPITAL; PHLEBOTOMY; PROCEDURES; VIROLOGY; ANALYZER; DRUG TREATMENT FAILURE; FEASIBILITY STUDY; HIV TEST; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; PREDICTIVE VALUE;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; VIRUS RNA;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLOOD SPECIMEN COLLECTION; DRIED BLOOD SPOT TESTING; FEMALE; HIV INFECTIONS; HIV-1; HOSPITALS; HUMANS; MALAWI; MALE; PHLEBOTOMY; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; VIRAL LOAD; VIREMIA;

EID: 84902764208     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2014.05.005     Document Type: Article

References (46)

1. WHO HIV/AIDS 2013, WHO, Geneva.
2. Bertagnolio S., Parkin N.T., Jordan M., Brooks J., Garcia-Lerma J.G. Dried blood spots for HIV-1 drug resistance and viral load testing: a review of current knowledge and WHO efforts for global HIV drug resistance surveillance. AIDS Rev 2010, 12:195-208.
3. Roberts T., Bygrave H., Fajardo E., Ford N. Challenges and opportunities for the implementation of virological testing in resource-limited settings. J Int AIDS Soc 2012, 15:17324.
4. Calmy A., Ford N., Hirschel B., Reynolds S.J., Lynen L., Goemaere E., et al. HIV viral load monitoring in resource-limited regions: optional or necessary?. Clin Infect Dis 2007, 44:128-134.
5. Chaiwarith R., Wachirakaphan C., Kotarathititum W., Praparatanaphan J., Sirisanthana T., Supparatpinyo K. Sensitivity and specificity of using CD4+ measurement and clinical evaluation to determine antiretroviral treatment failure in Thailand. Int J Infect Dis 2007, 11:413-416.
6. Keiser O., Tweya H., Boulle A., Braitstein P., Schecter M., Brinkhof M.W., et al. Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS 2009, 23:1867-1874.
7. Lynen L., Van Griensven J., Elliott J. Monitoring for treatment failure in patients on first-line antiretroviral treatment in resource-constrained settings. Curr Opin HIV AIDS 2010, 5:1-5.
8. Mee P., Fielding K.L., Charalambous S., Churchyard G.J., Grant A.D. Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS (London, England) 2008, 22:1971-1977.
9. Meya D., Spacek L.A., Tibenderana H., John L., Namugga I., Magero S., et al. Development and evaluation of a clinical algorithm to monitor patients on antiretrovirals in resource-limited settings using adherence, clinical and CD4 cell count criteria. J Int AIDS Soc 2009, 12:3.
10. Palombi L., Marazzi M.C., Guidotti G., Germano P., Buonomo E., Scarcella P., et al. Incidence and predictors of death, retention, and switch to second-line regimens in antiretroviral- treated patients in sub-Saharan African Sites with comprehensive monitoring availability. Clin Infect Dis 2009, 48:115-122.
11. Reynolds S.J., Nakigozi G., Newell K., Ndyanabo A., Galiwongo R., Boaz I., et al. Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS (London, England) 2009, 23:697-700.
12. Keiser O., MacPhail P., Boulle A., Wood R., Schechter M., Dabis F., et al. Accuracy of WHO CD4 cell count criteria for virological failure of antiretroviral therapy. Trop Med Int Health 2009, 14:1220-1225.
13. Moore D.M., Awor A., Downing R., Kaplan J., Montaner J.S., Hancock J., et al. CD4+ T-cell count monitoring does not accurately identify HIV-infected adults with virologic failure receiving antiretroviral therapy. J Acquir Immune Defic Syndr 2008, 49:477-484.
14. Costenaro P., Lundin R., Petrara M.R., Penazzato M., Massavon W., Kizito S., et al. Viral load detection using dried blood spots in a cohort of HIV-1-infected children in Uganda: correlations with clinical and immunological criteria for treatment failure. J Clin Microbiol 2014, [ahead of print]. 10.1128/JCM.00961-14.
15. Bagchi S., Kempf M.C., Westfall A.O., Maherya A., Willig J., Saag M.S. Can routine clinical markers be used longitudinally to monitor antiretroviral therapy success in resource-limited settings?. Clin Infect Dis 2007, 44:135-138.
16. Coutinho A., Mermin J., Ekwaru J., Were W., Bunnell R., Kahuaruza F., et al. Utility of routine viral load, CD4 cell count, and clinical monitoring among HIV-infected adults in Uganda: a randomized trial. BMJ 2011, 343:d6792.
17. Gupta R.K., Hill A., Sawyer A.W., Cozzi-Lepri A., von Wyl V., Yerly S., et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis 2009, 9:409-417.
18. Jaffar S., Birungi J., Grosskurth H., Amuron B., Namara G., Nabiryo C., et al. Use of WHO clinical stage for assessing patient eligibility to antiretroviral therapy in a routine health service setting in Jinja, Uganda. AIDS Res Ther 2008, 5:4.
19. Phillips A.N., Pillay D., Miners A.H., Bennett D.E., Gilks C.F., Lundgren J.D. Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. Lancet 2008, 371:1443-1451.
20. Schooley R.T. Viral load testing in resource-limited settings. Clin Infect Dis 2007, 44:139-140.
21. van Oosterhout J.J., Brown L., Weigel R., Kumwenda J.J., Mzinganjira D., Saukila N., et al. Diagnosis of antiretroviral therapy failure in Malawi: poor performance of clinical and immunological WHO criteria. Trop Med Int Health 2009, 14:856-861.
22. DART Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet 2010, 375:123-131.
23. Badri M., Wood R. Usefulness of total lymphocyte count in monitoring highly active antiretroviral therapy in resource-limited settings. AIDS 2003, 17:541-545.
24. Kantor R., Diero L., Delong A., Kamle L., Muyonga S., Mambo F., et al. Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. Clin Infect Dis 2009, 49:454-462.
25. Jani I.V., Peter T.F. How point-of-care testing could drive innovation in global health. N Engl J Med 2013, 368:2319-2324.
26. Garrido C., Zahonero N., Corral A., Arredondo M., Soriano V., de Mendoza C. Correlation between human immunodeficiency virus type 1 (HIV-1) RNA measurements obtained with dried blood spots and those obtained with plasma by use of Nuclisens EasyQ HIV-1 and Abbott RealTime HIV load tests. J Clin Microbiol 2009, 47:1031-1036.
27. Waters L., Kambugu A., Tibenderana H., Meya D., John L., Mandalia S., et al. Evaluation of filter paper transfer of whole-blood and plasma samples for quantifying HIV RNA in subjects on antiretroviral therapy in Uganda. J Acquir Immune Defic Syndr 2007, 46:590-593.
28. Fajardo E., Metcalf C.A., Chaillet P., Aleixo L., Pannus P., Panunzi I., et al. Prospective evaluation of the diagnostic accuracy of dried blood spots from finger-prick for the determination of HIV-1 viral load with the NucliSENS Easy-Q HIV-1 v2.0 in Malawi. J Clin Microbiol 2014, 52:1343.
29. Glencross D.K., Coetzee L.M., Faal M., Masango M., Stevens W.S., Venter W.F., et al. Performance evaluation of the Pima point-of-care CD4 analyser using capillary blood sampling in field tests in South Africa. J Int AIDS Soc 2012, 15:3.
30. Diaw P.A., Daneau G., Coly A.A., Ndiaye B.P., Wade D., Camara M., et al. Multisite evaluation of a point-of-care instrument for CD4(+) T-cell enumeration using venous and finger-prick blood: the PIMA CD4. J Acquir Immune Defic Syndr 2011, 58:e103-e111.
31. Arredondo M., Garrido C., Parkin N., Zahonero N., Bertagnolio S., Soriano V., et al. Comparison of HIV-1 RNA measurements obtained by using plasma and dried blood spots in the automated abbott real-time viral load assay. J Clin Microbiol 2012, 50:569-572.
32. Ouma K.N., Basavaraju S.V., Okonji J.A., Williamson J., Thomas T.K., Mills L.A., et al. Evaluation of quantification of HIV-1 RNA viral load in plasma and dried blood spots by use of the semiautomated Cobas Amplicor assay and the fully automated Cobas Ampliprep/TaqMan assay, version 2.0, in Kisumu, Kenya. J Clin Microbiol 2013, 51:1208-1218.
33. Huang S., Erickson B., Mak W.B., Salituro J., Abravaya K. A novel RealTime HIV-1 Qualitative assay for the detection of HIV-1 nucleic acids in dried blood spots and plasma. J Virol Methods 2011, 178:216-224.
34. Johannessen A., Garrido C., Zahonero N., Sandvik L., Naman E., Kivuyo S.L., et al. Dried blood spots perform well in viral load monitoring of patients who receive antiretroviral treatment in rural Tanzania. Clin Infect Dis 2009, 49:976-981.
35. Johannessen A., Troseid M., Calmy A. Dried blood spots can expand access to virological monitoring of HIV treatment in resource-limited settings. J Antimicrob Chemother 2009, 64:1126-1129.
36. Johannessen A. Dried blood spots in HIV monitoring: applications in resource-limited settings. Bioanalysis 2010, 2:1893-1908.
37. Mbida A.D., Sosso S., Flori P., Saoudin H., Lawrence P., Monny-Lobe M., et al. Measure of viral load by using the Abbott Real-Time HIV-1 assay on dried blood and plasma spot specimens collected in 2 rural dispensaries in Cameroon. J Acquir Immune Defic Syndr 2009, 52:9-16.
38. Vidya M., Saravanan S., Rifkin S., Solomon S.S., Waldrop G., Mayer K.H., et al. Dried blood spots versus plasma for the quantitation of HIV-1 RNA using a real-Time PCR, m2000rt assay. J Virol Methods 2012, 181:177-181.
39. Neogi U., Gupta S., Rodridges R., Sahoo P.N., Rao S.D., Rewari B.B., et al. Dried blood spot HIV-1 RNA quantification: a useful tool for viral load monitoring among HIV-infected individuals in India. Indian J Med Res 2012, 136:956-962.
40. Rottinghaus E.K., Ugbena R., Diallo K., Bassey O., Azeez A., Devos J., et al. Dried blood spot specimens are a suitable alternative sample type for HIV-1 viral load measurement and drug resistance genotyping in patients receiving first-line antiretroviral therapy. Clin Infect Dis 2012, 54:1187-1195.
41. Brambilla D., Jennings C., Aldrovandi G., Bremer J., Comeau A.M., Cassol S.A., et al. Multicenter evaluation of use of dried blood and plasma spot specimens in quantitative assays for human immunodeficiency virus RNA: measurement, precision, and RNA stability. J Clin Microbiol 2003, 41:1888-1893.
42. Hamers R.L., Smit P.W., Stevens W., Schuurman R., Rinke de Wit T.F. Dried fluid spots for HIV type-1 viral load and resistance genotyping: a systematic review. Antivir Ther 2009, 14:619-629.
43. Fiscus S.A., Brambilla D., Grosso L., Schock J., Cronin M. Quantitation of human immunodeficiency virus type 1 RNA in plasma by using blood dried on filter paper. J Clin Microbiol 1998, 36:258-260.
44. Rottinghaus E., Bile E., Modukanele M., Maruping M., Mine M., Nkengasong J., et al. Comparison of Ahlstrom grade 226, Munktell TFN, and Whatman 903 filter papers for dried blood spot specimen collection and subsequent HIV-1 load and drug resistance genotyping analysis. J Clin Microbiol 2013, 51:55-60.
45. WHO Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection 2013, WHO, Geneva, Switzerland.
46. Viljoen J., Gampini S., Danaviah S., Valea D., Pillay S., Kania D., et al. Dried blood spot HIV-1 RNA quantification using open real-time systems in South Africa and Burkina Faso. J Acquir Immune Defic Syndr 2010, 55:290-298.